High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.
Cancer Rep (Hoboken)
; 7(4): e2061, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38662349
ABSTRACT
BACKGROUND:
Despite advances in therapeutics for adverse-risk acute myeloid leukaemia (AML), overall survival remains poor, especially in refractory disease. Comprehensive tumour profiling and pre-clinical drug testing can identify effective personalised therapies. CASE We describe a case of ETV6-MECOM fusion-positive refractory AML, where molecular analysis and in vitro high throughput drug screening identified a tolerable, novel targeted therapy and provided rationale for avoiding what could have been a toxic treatment regimen. Ruxolitinib combined with hydroxyurea led to disease control and enhanced quality-of-life in a patient unsuitable for intensified chemotherapy or allogeneic stem cell transplantation.CONCLUSION:
This case report demonstrates the feasibility and role of combination pre-clinical high throughput screening to aid decision making in high-risk leukaemia. It also demonstrates the role a JAK1/2 inhibitor can have in the palliative setting in select patients with AML.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Ensayos Analíticos de Alto Rendimiento
/
Toma de Decisiones Clínicas
Idioma:
En
Revista:
Cancer Rep (Hoboken)
Año:
2024
Tipo del documento:
Article